HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

L 663536

orally active leukotriene biosynthesis inhibitor; structure in first source

Also Known As:

3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid; L-663,536; MK 886; MK-886; MK886 cpd; 1H-Indole-2-propanoic acid, 1-((4-chlorophenyl)methyl)-3-((1,1-dimethylethyl)thio)-alpha,alpha-dimethyl-5-(1-methylethyl)-

Networked: 64 relevant articles (5 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Indoles: 95
    - L 663536: 64

Experts

1.	Harris, J E: 6 articles (01/2005 - 07/2000)
2.	Anderson, K M: 6 articles (01/2005 - 07/2000)
3.	Hofmanová, Jirina: 4 articles (11/2008 - 06/2006)
4.	Kozubík, Alois: 4 articles (11/2008 - 06/2006)
5.	Alrefai, W A: 4 articles (01/2005 - 07/2000)
6.	Fedorocko, Peter: 3 articles (11/2008 - 08/2006)
7.	Mikes, Jaromír: 3 articles (11/2008 - 08/2006)
8.	Sacková, Veronika: 3 articles (11/2008 - 08/2006)
9.	Kleban, Ján: 3 articles (11/2008 - 08/2006)
10.	Horváth, Viktor: 3 articles (11/2008 - 08/2006)

Related Diseases

1.	Asthma (Bronchial Asthma) 04/01/1993 - "This indicates that LT play a role in allergen-induced asthmatic reactions in humans in vivo and that LT synthesis inhibitors such as MK-886 should be further explored for the treatment of asthma." 01/01/1991 - "Development of novel leukotriene--based anti-asthma drugs: MK-886 and MK-571." 01/01/1992 - "MK-886 was effective in Ascaris-induced asthma in squirrel monkeys, in rat carrageenan pleurisy, in rat Arthus pleurisy, and (topically) in guinea-pig ear oedema induced by A23187.(ABSTRACT TRUNCATED AT 400 WORDS)" 04/01/1993 - "To elucidate the role of leukotrienes (LT) in allergic asthma in humans the effect of MK-886, an LT biosynthesis inhibitor, was evaluated on antigen-induced early (EAR) and late (LAR) asthmatic reactions and bronchial responsiveness to histamine. " 07/01/1997 - "Many of these medications appear to be effective in the treatment of asthma (BAYX-1005; MK-0591; MK-886; AA-681; A-64077; ZD-2138; U-60257; FR-110302; BI-6239; A-78773; ABT-761; L-746530; L-699333; ZM-230487). "
2.	Inflammation 06/01/2000 - "MK-886 inhibited colonic LTB(4) production but did not reduce diarrhoea, inflammation, or mucosal damage. " 05/01/1992 - "The specific leukotriene biosynthesis inhibitor MK-886 administered prior to induction of colitis healed macroscopic ulceration and inflammation but not fluid absorptive injury. " 05/01/1992 - "Combining MK-886 with misoprostol treatment improved not only macroscopic ulceration and inflammation but also provided a synergistic effect that maintained net colonic fluid absorption at noncolitic control levels. " 06/01/2000 - "Myeloperoxidase activity was measured and histological inflammation and damage were assessed at five days in control and infected animals and after treatment of infected animals with the LTB(4) synthesis inhibitor MK-886. " 08/01/1992 - "Neither OKY-046 (a thromboxane synthase inhibitor) nor MK-886 (a 5-lipoxygenase inhibitor) altered the glomerular inflammation of NTN. "
3.	Atherosclerosis 05/09/2008 - "Increased activity of the enzymatic 5-lipoxygenase (5-LOX, 5LO) pathway is a contributing factor in atherosclerosis and a 5-LOX inhibitor, MK-886, is beneficial in animal models of atherosclerosis. " 03/01/2006 - "Our results show for the first time that inhibition of FLAP by MK-886 reduces development of atherosclerosis in gene-targeted apoE/LDLR-DKO mice." 03/01/2006 - "Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice." 09/01/2007 - "Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. " 03/01/2006 - "We hypothesized that MK-886, an inhibitor of FLAP, could attenuate the development of atherosclerosis in the atherogenic apolipoprotein E/low density lipoprotein receptor (apoE/LDLR) double knockout (DKO) mouse model. "
4.	Pleurisy (Pleuritis) 01/01/1992 - "MK-886 was effective in Ascaris-induced asthma in squirrel monkeys, in rat carrageenan pleurisy, in rat Arthus pleurisy, and (topically) in guinea-pig ear oedema induced by A23187.(ABSTRACT TRUNCATED AT 400 WORDS)" 01/25/1991 - "The 5-lipoxygenase inhibitors WY-50,295 tromethamine, A-64,077, L-663,536 and ICI-207,968 were compared in a reverse passive Arthus reaction-induced pleurisy model of eicosanoid biosynthesis in the rat. "
5.	Anoxia (Hypoxia) 08/01/1999 - "Destruction of Kupffer cells with GdCl(3) (20 mg/kg i.v. 24 h before explantation) or inhibition of formation of leukotrienes with MK-886 (50 microM in University of Wisconsin or rinse solution) also minimized hypoxia and improved survival after transplantation. " 01/01/2014 - "In a subset of cells, the ALOX5 inhibitor, zileuton, or the 5-lipoxygenase activating protein inhibitor, MK-886, was administered during hypoxia exposure. "

Related Drugs and Biologics

1.	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)
2.	Leukotrienes
3.	zileuton (Zyflo)
4.	A 78773
5.	MK 0591
6.	Misoprostol (Cytotec)
7.	Carrageenan
8.	Calcimycin (A23187)
9.	L 746530
10.	atreleuton

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Heart Transplantation (Grafting, Heart)
3.	Photochemotherapy (Photodynamic Therapy)
4.	Induced Hypothermia
5.	Resuscitation